Analysis of Bordetella pertussis pertactin and pertussis toxin types from Queensland, Australia, 1999-2003

BMC Infectious Diseases

Volumn 6, Issue , 2006, Pages

  Byrne, Shane ^a   Slack, Andrew T ^a,b  

^a QUEENSLAND HEALTH   (Australia)

^b Sullivan Nicolaides Pathology   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

ACELLULAR VACCINE; PERTACTIN; PERTUSSIS TOXIN; PERTUSSIS VACCINE;

ADOLESCENT; ALLELE; ANALYTICAL EQUIPMENT; ARTICLE; AUSTRALIA; BACTERIAL STRAIN; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATION; BORDETELLA PERTUSSIS; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; FEMALE; GENOTYPE; HUMAN; MALE; MEDICAL RESEARCH; NONHUMAN; PERTUSSIS; PROTEIN DETERMINATION; PROTEIN VARIANT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VACCINE PRODUCTION;

ADOLESCENT; ADULT; ALLELES; BACTERIAL OUTER MEMBRANE PROTEINS; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; FEMALE; GENETIC VARIATION; HUMANS; INFANT; INFANT, NEWBORN; MALE; PERTUSSIS TOXIN; PERTUSSIS VACCINE; QUEENSLAND; TIME FACTORS; VIRULENCE FACTORS, BORDETELLA;

EID: 33646565350     PISSN: 14712334     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-6-53     Document Type: Article

References (39)

1. The Australian Immunisation Handbook. 8th edition. Canberra, National Health and Medical Research Council.; 2003.
2. McIntyre P, Amin J, Gidding H, Hull B, Torvaldsen S, Tucker A, Turnbull F, Burgess M: Vaccine preventable diseases and vaccination coverage in Australia, 1993-1998. Commun Dis Intell 2000, Suppl:v-83.
3. Vaccine-preventable diseases and vaccination coverage in Australia, 1999-2000. N S W Public Health Bull 2003, 14:94.
4. Brotherton J, McIntyre P, Puech M, Wang H, Gidding H, Hull B, Lawrence G, MacIntyre R, Wood N, Armstrong D: Vaccine preventable diseases and vaccination coverage in Australia 2001 to 2002. Commun Dis Intell 2004, 28 Suppl 2:vii-S116.
5. Miller M, Roche P, Yohannes K, Spencer J, Bartlett M, Brotherton J, Hutchinson J, Kirk M, McDonald A, Vadjic C: Australia's notifiable diseases status, 2003: Annual report of the National Notifiable Diseases Surveillance System. Commun Dis Intell 2005, 29:1-61.
6. National Notifiable Diseases Surveillance System [http://wwwl.health.gov.au/cda/Source/Rpt 4 sel.cfm]
7. de Melker HE, Schellekens JF, Neppelenbroek SE, Mooi FR, Rumke HC, Conyn-van Spaendonck MA, Reemergence of pertussis in the highly vaccinated population of the Netherlands: observations on surveillance data. Emerg Infect Dis 2000, 6:348-357.
8. Guris D, Strebel PM, Bardenheier B, Brennan M, Tachdjian R, Finch E, Wharton M, Livengood JR: Changing epidemiology of pertussis in the United States: increasing reported incidence among adolescents and adults, 1990-1996. Clin Infect Dis 1999, 28:1230-1237.
9. Mooi FR, van Loo IH, King AJ: Adaptation of Bordetella pertussis to vaccination: a cause for its reemergence? Emerg Infect Dis 2001, 7:526-528.
10. Bass JW, Wittler RR: Return of epidemic pertussis in the United States. Pediatr Infect Dis J 1994, 13:343-345.
11. Godfroid F, Denoel P, Poolman J: Are vaccination programs and isolate polymorphism linked to pertussis re-emergence? Expect Rev Vaccines 2005, 4:757-778.
12. von Konig CH, Halperin S, Riffelmann M, Guiso N: Pertussis of adults and infants. Lancet Infect Dis 2002, 2:744-750.
13. Andrews R, Herceg A, Roberts C: Pertussis notifications in Australia, 1991 to 1997. Commun Dis Intell 1997, 21:145-148.
14. Forsyth KD, Campins-Marti M, Caro J, Cherry JD, Greenberg D, Guiso N, Heininger U, Schellekens J, Tan T, von Konig CH, Plotkin S: New pertussis vaccination strategies beyond infancy: recommendations by the global pertussis initiative. Clin Infect Dis 2004, 39:1802-1809.
15. Forsyth K, Tan T, von Konig CH, Caro JJ, Plotkin S: Potential strategies to reduce the burden of pertussis. Pediatr Infect Dis J 2005, 24:S69-74.
16. Forsyth K, Nagai M, Lepetic A, Trindade E: Pertussis immunization in the global pertussis initiative international region: recommended strategies and implementation considerations. Pediatr Infect Dis J 2005, 24:S93-7.
17. Poynten M, Hanlon M, Irwig L, Gilbert GL: Serological diagnosis of pertussis: evaluation of IgA against whole cell and specific Bordetella pertussis antigens as markers of recent infection. Epidemiol Infect 2002, 128:161-167.
18. Notifiable Diseases Report 1997-2001 [http://www.health.qld.gov.au/phs/Documents/cdu/15896.pdf]
19. Mooi FR, van Oirschot H, Heuvelman K, van der Heide HG, Gaastra W, Willems RJ: Polymorphism in the Bordetella pertussis virulence factors P.69/pertactin and pertussis toxin in The Netherlands: temporal trends and evidence for vaccine-driven evolution. Infect Immun 1998, 66:670-675.
20. Fry NK, Neal S, Harrison TG, Miller E, Matthews R, George RC: Genotypic variation in the Bordetella pertussis virulence factors pertactin and pertussis toxin in historical and recent clinical isolates in the United Kingdom. Infect Immun 2001, 69:5520-5528.
21. Denoel P, Godfroid F, Guiso N, Hallander H, Poolman J: Comparison of acellular pertussis vaccines-induced immunity against infection due to Bordetella pertussis variant isolates in a mouse model. Vaccine 2005, 23:5333-5341.
22. Guiso N, Boursaux-Eude C, Weber C, Hausman SZ, Sato H, Iwaki M, Kamachi K, Konda T, Burns DL: Analysis of Bordetella pertussis isolates collected in Japan before and after introduction of acellular pertussis vaccines. Vaccine 2001, 19:3248-3252.
23. Kodama A, Kamachi K, Horiuchi Y, Konda T, Arakawa Y: Antigenic divergence suggested by correlation between antigenic variation and pulsed-field gel electrophoresis profiles of Bordetella pertussis isolates in Japan. J Clin Microbiol 2004, 42:5453-5457.
24. van Amersfoorth SC, Schouls LM, van der Heide HG, Advani A, Hallander HO, Bondeson K, von Konig CH, Riffelmann M, Vahrenholz C, Guiso N, Caro V, Njamkepo E, He Q, Mertsola J, Mooi FR: Analysis of Bordetella pertussis populations in European countries with different vaccination policies. J Clin Microbiol 2005, 43:2837-2843.
25. Caro V, Njamkepo E, Van Amersfoorth SC, Mooi FR, Advani A, Hallander HO, He Q, Mertsola J, Riffelmann M, Vahrenholz C, Von Konig CH, Guiso N: Pulsed-field gel electrophoresis analysis of Bordetella pertussis populations in various European countries with different vaccine policies. Microbes Infect 2005, 7:976-982.
26. Muyldermans G, Pierard D, Hoebrekx N, Advani R, Van Amersfoorth S, De Schutter I, Soetens O, Eeckhout L, Malfroot A, Lauwers S: Simple Algorithm for Identification of Bordetella pertussis Pertactin Gene Variants. J Clin Microbiol 2004, 42:1614-1619.
27. Fiett J, Letowska I, Gniadkowski M, Hryniewicz W: The new strategy for allele identification of the genes coding for pertussis toxin subunit S1 (ptx S1) and pertactin (prn) in Bordetella pertussis. J Microbiol Methods 2003, 55:651-666.
28. Makinen J, Viljanen MK, Mertsola J, Arvilommi H, He Q: Rapid identification of Bordetella pertussis pertactin gene variants using LightCycler real-time polymerase chain reaction combined with melting curve analysis and gel electrophoresis. Emerg Infect Dis 2001, 7:952-958.
29. Tamura M, Nogimori K, Murai S, Yajima M, Ito K, Katada T, Ui M, Ishii S: Subunit structure of islet-activating protein, pertussis toxin, in conformity with the A-B model. Biochemistry 1982, 21:5516-5522.
30. Sekura RD, Fish F, Manclark CR, Meade B, Zhang YL: Pertussis toxin. Affinity purification of a new ADP-ribosyltransferase. J Biol Chem 1983, 258:14647-14651.
31. Makinen J, Mertsola J, Viljanen MK, Arvilommi H, He Q: Rapid typing of Bordetella pertussis pertussis toxin gene variants by LightCycler real-time PCR and fluorescence resonance energy transfer hybridization probe melting curve analysis. J Clin Microbiol 2002, 40:2213-2216.
32. Poynten M, McIntyre PB, Mooi FR, Heuvelman KJ, Gilbert GL: Temporal trends in circulating Bordetella pertussis strains in Australia. Epidemiol Infect 2004, 132:185-193.
33. Mooi FR, Hallander H, Wirsing von Konig CH, Hoet B, Guiso N: Epidemiological typing of Bordetella pertussis isolates: recommendations for a standard methodology. Eur J Clin Microbiol Infect Dis 2000, 19:174- 181.
34. Strike PW: Statistical Methods in Laboratory Medicine. Oxford, Butterworth Heinemann; 1991.
35. Greenberg DP, von Konig CH, Heininger U: Health burden of pertussis in infants and children. Pediatr Infect Dis J 2005, 24:S39-43.
36. Weber C, Boursaux-Eude C, Coralie G, Caro V, Guiso N: Polymorphism of Bordetella pertussis isolates circulating for the last 10 years in France, where a single effective whole-cell vaccine has been used for more than 30 years. J Clin Microbiol 2001, 39:4396-4403.
37. Mooi FR, He Q, van Oirschot H, Mertsola J: Variation in the Bordetella pertussis virulence factors pertussis toxin and pertactin in vaccine strains and clinical isolates in Finland. Infect Immun 1999, 67:3133-3134.
38. Kourova N, Caro V, Weber C, Thiberge S, Chuprinina R, Tseneva G, Guiso N: Comparison of the Bordetella pertussis and Bordetella parapertussis isolates circulating in Saint Petersburg between 1998 and 2000 with Russian vaccine strains. J Clin Microbiol 2003, 41:3706-3711.
39. Cassiday P, Sanden G, Heuvelman K, Mooi F, Bisgard KM, Popovic T: Polymorphism in Bordetella pertussis pertactin and pertussis toxin virulence factors in the United States, 1935-1999. J Infect Dis 2000, 182:1402-1408.